AstraZeneca surpassed profitability expectations as it disclosed its third-quarter earnings, even as it confronts a significant legal challenge alleging that the effectiveness of its vaccines was greatly exaggerated.
AstraZeneca (LON:AZN) reaches a monthly peak due to positive outcomes from a breast cancer medication trial.
Shares of AstraZeneca PLC (LSE: AZN) have witnessed a 2% increase, surpassing 11,100p for the first time in a month, following the company’s announcement of promising results from an ongoing
AstraZeneca (LON:AZN) and Alexion collaborate with the FDA to broaden the US label for Ultomiris.
AstraZeneca PLC (LON: AZN) announced that the US Food and Drug Administration (FDA) has requested a risk assessment and mitigation strategy in response to a proposal to broaden the application
AstraZeneca subsidiary finalizes a US$1bn deal with Pfizer for rare diseases.
AstraZeneca has reported a stronger-than-anticipated performance in the second quarter, with robust sales from its leading cancer drugs offsetting the decline in Covid vaccine sales.